Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Dose-Exploratory, Positive-Control Clinical Trial Evaluating the Safety and Immunogenicity of the 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) Following Administration in Individuals Aged 2 Months (Minimum 6 Weeks) and Older

NCT07600983 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT07600983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07600983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Dose-Exploratory, Positive-Control Clinical Trial Evaluating the Safety and Immunogenicity of the 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) Following Administration in Individuals Aged 2 Months (Minimum 6 Weeks) and Older
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 24, 2026
Completion date
December 30, 2027
Enrollment
854 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

streptococcus pneumoniae infection